Entasis Therapeutics Holdings Inc. News Releases https://investors.entasistx.com/ Entasis Therapeutics Holdings Inc. News Releases en Entasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-reports-first-quarter-2019-financial Transformative start to the year with the first Phase 3 trial underway and key additions to the leadership team WALTHAM, Mass. , May 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of Tue, 14 May 2019 07:30:00 -0400 Entasis Therapeutics Holdings Inc. News Releases 6976 Entasis Therapeutics to Participate in the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-participate-5th-annual-suntrust-robinson WALTHAM, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of Tue, 30 Apr 2019 16:01:00 -0400 Entasis Therapeutics Holdings Inc. News Releases 6941 Entasis Therapeutics Strengthens Leadership Team with Appointment of Eric Kimble as Chief Commercial Officer https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-strengthens-leadership-team-appointment Kimble to lead global commercialization strategy for the Company’s late-stage antimicrobial pipeline WALTHAM, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel Tue, 23 Apr 2019 08:00:00 -0400 Entasis Therapeutics Holdings Inc. News Releases 6936 Entasis Therapeutics Announces the Appointment of Elizabeth Keiley as General Counsel https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-announces-appointment-elizabeth-keiley WALTHAM, Mass. , April 16, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of Elizabeth Keiley as General Counsel. Ms. Tue, 16 Apr 2019 08:00:00 -0400 Entasis Therapeutics Holdings Inc. News Releases 6931 Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019 https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-announces-multiple-data-presentations CEO Manos Perros, PhD to present on Industry Panel “Therapeutics Pipeline Corner” on April 14 WALTHAM, Mass. , April 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious Wed, 10 Apr 2019 08:00:00 -0400 Entasis Therapeutics Holdings Inc. News Releases 6911 Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-initiates-global-phase-3-pivotal-trial WALTHAM, Mass. , April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious drug-resistant infections, today announced the initiation of the ATTACK ( A cinetobacter T reatment T Thu, 04 Apr 2019 08:00:00 -0400 Entasis Therapeutics Holdings Inc. News Releases 6901 Entasis Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Conference in London https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-present-hc-wainwright-co-global-life WALTHAM, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer, Tue, 02 Apr 2019 08:00:00 -0400 Entasis Therapeutics Holdings Inc. News Releases 6891 Entasis Therapeutics Reports Full Year 2018 Financial Results and Provides Business Update https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-reports-full-year-2018-financial-results On track to commence two Phase 3 clinical trials in 2019 WALTHAM, Mass. , March 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its full Fri, 29 Mar 2019 07:30:00 -0400 Entasis Therapeutics Holdings Inc. News Releases 6871 Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-present-39th-annual-cowen-healthcare WALTHAM, Mass. , March 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer, Wed, 06 Mar 2019 16:01:00 -0500 Entasis Therapeutics Holdings Inc. News Releases 6846 Entasis Therapeutics Receives Positive Feedback from FDA End-of-Phase 2 Meeting for ETX2514SUL; Signs Rapid Diagnostic Agreement with bioMérieux https://investors.entasistx.com/news-releases/news-release-details/entasis-therapeutics-receives-positive-feedback-fda-end-phase-2 Entasis to incorporate BIOFIRE® FILMARRAY® System, a rapid molecular diagnostic platform, into ETX2514SUL Phase 3 clinical trial, on track to initiate in 1Q 2019 WALTHAM, Mass. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical Tue, 05 Feb 2019 08:00:00 -0500 Entasis Therapeutics Holdings Inc. News Releases 6836